Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2010

View Archived Issues

AstraZeneca reports results from Q4 2009 and the year's R&D highlights

Alnylam initiates phase IIb trial of ALN-RSV01 in RSV-infected lung transplant patients

Curemark's CM-AT autism treatment obtains FDA fast track status

DNA prime/rAd5 boost vaccine regimen safe and immunogenic in HIV

Dual-acting NMDA antagonist neuroprotective in rat model of spinal cord injury

EnzymeRx provides clinical update on pegsitacase

Dual PI3K/mTOR inhibitor with potent preclinical antitumor activity enters phase I trial

Merck T-type calcium channel antagonists effective in models of CNS disorders

Novel HSP90 inhibitors identified by sanofi-aventis

Ranbaxy Laboratories discloses new antibacterial agents

Avexa discovers HIV integrase inhibitors for AIDS therapy

FDA approves once-daily Mirapex ER for early Parkinson's disease

PPARdelta agonists discovered at sanofi-aventis

Ceragenix and BexPharm enter into agreement for EpiCeram

Viamet and Novartis partner for metalloenzyme inhibitors

Hematopoietic prostaglandin-D2 synthase inhibitors claimed by Pfizer for asthma therapy

BioSante reports phase III LibiGel safety data

Concert Pharmaceuticals describes new GABA(A) receptor inverse agonists

GSK and FDA present safety update on Avandia for type 2 diabetes

Takeda and Affymax begin phase III trial of Hematide in chronic renal failure

FDA grants marketing approval for Gilead's Cayston for CF patients with P. aeruginosa

Amylin and Takeda to begin phase III trial of pramlintide/metreleptin in obesity

Lilly, Merck and Pfizer form Asian Cancer Research Group

Additional agents included in strategic collaboration of ExonHit and Allergan

Cyto Pulse obtains Swedish approval for phase I HIV/DNA vaccine trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
Alicorn synthesizes new AAK1 inhibitors
BioWorld Science
Researchers from Alicorn Pharmaceutical Co. Ltd. and Jiangsu Alicorn Pharmaceutical Co. Ltd. have disclosed crystalline salts of compounds acting as...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...
Saniona reports preclinical data for SAN-2668
BioWorld Science
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive...
CC-3 antibody shows antitumoral activity in penile cancer
BioWorld Science
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies...